161 related articles for article (PubMed ID: 26471485)
1. Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Luminari S; Galimberti S; Versari A; Biasoli I; Anastasia A; Rusconi C; Ferrari A; Petrini M; Manni M; Federico M
Haematologica; 2016 Feb; 101(2):e66-8. PubMed ID: 26471485
[No Abstract] [Full Text] [Related]
2. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).
Luminari S; Biasoli I; Versari A; Rattotti S; Bottelli C; Rusconi C; Merli F; Spina M; Ferreri AJ; Zinzani PL; Gallamini A; Franceschetto A; Boccomini C; Franceschetti S; Salvi F; Raimondo FD; Carella AM; Micol Q; Balzarotti M; Musto P; Federico M
Ann Oncol; 2014 Feb; 25(2):442-7. PubMed ID: 24412823
[TBL] [Abstract][Full Text] [Related]
3. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.
Luminari S; Biasoli I; Arcaini L; Versari A; Rusconi C; Merli F; Spina M; Ferreri AJ; Zinzani PL; Gallamini A; Mastronardi S; Boccomini C; Gaidano G; D'Arco AM; Di Raimondo F; Carella AM; Santoro A; Musto P; Federico M
Ann Oncol; 2013 Aug; 24(8):2108-12. PubMed ID: 23585513
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Galimberti S; Luminari S; Ciabatti E; Grassi S; Guerrini F; Dondi A; Marcheselli L; Ladetto M; Piccaluga PP; Gazzola A; Mannu C; Monitillo L; Mantoan B; Del Giudice I; Della Starza I; Cavalli M; Arcaini L; Tucci A; Palumbo GA; Rigacci L; Pulsoni A; Vitolo U; Boccomini C; Vallisa D; Bertoldero G; Gaidano G; Musto P; Petrini M; Federico M
Clin Cancer Res; 2014 Dec; 20(24):6398-405. PubMed ID: 25316810
[TBL] [Abstract][Full Text] [Related]
5. Primary gastrointestinal follicular lymphoma with histological transformation.
Hangai S; Nakamura F; Kamikubo Y; Ichikawa M; Suzuki H; Yoshida S; Yamada A; Takazawa Y; Fukayama M; Koike K; Kurokawa M
Ann Hematol; 2013 Jul; 92(7):993-4. PubMed ID: 23271213
[No Abstract] [Full Text] [Related]
6. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
7. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
[TBL] [Abstract][Full Text] [Related]
8. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Marcheselli L; Bari A; Anastasia A; Botto B; Puccini B; Dondi A; Carella AM; Alvarez I; Chiarenza A; Arcari A; Salvi F; Federico M
Br J Haematol; 2015 May; 169(4):544-51. PubMed ID: 25817296
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.
Kostakoglu L; Goy A; Martinelli G; Caballero D; Crump M; Gaidano G; Baetz T; Buckstein R; Fine G; Fingerle-Rowson G; Berge C; Sahin D; Press O; Sehn L
Leuk Lymphoma; 2017 Feb; 58(2):372-381. PubMed ID: 27339738
[TBL] [Abstract][Full Text] [Related]
10. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?
Janikova A; Bolcak K; Pavlik T; Mayer J; Kral Z
Clin Lymphoma Myeloma; 2008 Oct; 8(5):287-93. PubMed ID: 18854283
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.
Zinzani PL; Musuraca G; Alinari L; Fanti S; Tani M; Stefoni V; Marchi E; Fina M; Pellegrini C; Castellucci P; Farsad M; Baccarani M
Clin Lymphoma Myeloma; 2007 Jan; 7(4):291-5. PubMed ID: 17324337
[TBL] [Abstract][Full Text] [Related]
12. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Ladetto M; Lobetti-Bodoni C; Mantoan B; Ceccarelli M; Boccomini C; Genuardi E; Chiappella A; Baldini L; Rossi G; Pulsoni A; Di Raimondo F; Rigacci L; Pinto A; Galimberti S; Bari A; Rota-Scalabrini D; Ferrari A; Zaja F; Gallamini A; Specchia G; Musto P; Rossi FG; Gamba E; Evangelista A; Vitolo U;
Blood; 2013 Nov; 122(23):3759-66. PubMed ID: 24085766
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
14. Debate on the value of end-of-treatment FDG-PET response evaluation in follicular lymphoma.
Adams HJA; Kwee TC
Acta Oncol; 2017 Dec; 56(12):1789-1791. PubMed ID: 28712315
[No Abstract] [Full Text] [Related]
15. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
[TBL] [Abstract][Full Text] [Related]
16. Residual Anatomical Disease in Diffuse Large B-Cell Lymphoma Patients With FDG-PET-Based Complete Response After First-Line R-CHOP Therapy: Does It Have Any Prognostic Value?
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
J Comput Assist Tomogr; 2015; 39(5):810-5. PubMed ID: 26035406
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategies in limited stage follicular NHL.
Hoppe RT
Best Pract Res Clin Haematol; 2011 Jun; 24(2):179-86. PubMed ID: 21658617
[TBL] [Abstract][Full Text] [Related]
18. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M
J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699
[TBL] [Abstract][Full Text] [Related]
19. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
